ABVC BioPharma (NASDAQ:ABVC) Trading Up 11.3% – Here’s Why

ABVC BioPharma, Inc. (NASDAQ:ABVC) shares were up 11.3% on Wednesday . The stock traded as high as $1.13 and last traded at $1.08. Approximately 141,320 shares changed hands during mid-day trading, an increase of 170% from the average daily volume of 52,307 shares. The stock had previously closed at $0.9701.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ABVC BioPharma in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, ABVC BioPharma presently has an average rating of “Sell”.

ABVC BioPharma Stock Up 11.3%

The company has a market capitalization of $27.48 million, a PE ratio of -2.70 and a beta of 0.28. The business has a 50 day simple moving average of $1.51 and a 200 day simple moving average of $2.24.

ABVC BioPharma (NASDAQ:ABVC) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.11) earnings per share for the quarter.

Institutional Trading of ABVC BioPharma

Several large investors have recently bought and sold shares of ABVC. Geode Capital Management LLC increased its stake in ABVC BioPharma by 7.7% during the 4th quarter. Geode Capital Management LLC now owns 202,365 shares of the company’s stock valued at $431,000 after purchasing an additional 14,553 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of ABVC BioPharma during the third quarter worth $60,000. Finally, Citadel Advisors LLC purchased a new stake in shares of ABVC BioPharma during the third quarter valued at $48,000. Hedge funds and other institutional investors own 11.38% of the company’s stock.

ABVC BioPharma Company Profile

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.